Anti-Müllerian hormone receptor defect
- 31 December 2006
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 20 (4), 599-610
- https://doi.org/10.1016/j.beem.2006.09.004
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regressionDevelopment, 2006
- Persistent Mullerian duct syndrome caused by both a 27‐bp deletion and a novel splice mutation in the MIS type II receptor geneBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Synergistic Cooperation between the β-Catenin Signaling Pathway and Steroidogenic Factor 1 in the Activation of the Mullerian Inhibiting Substance Type II ReceptorJournal of Biological Chemistry, 2003
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003
- Requirement of Bmpr1a for Müllerian duct regression during male sexual developmentNature Genetics, 2002
- Autosomal Recessive Segregation of a Truncating Mutation of Anti-Mullerian Type II Receptor in a Family Affected by the Persistent Mullerian Duct Syndrome Contrasts with Its Dominant Negative Activity in VitroJournal of Clinical Endocrinology & Metabolism, 2001
- Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 ExpressionMolecular Endocrinology, 2001
- Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated PathwayJournal of Biological Chemistry, 2000
- Engagement of Bone Morphogenetic Protein Type IB Receptor and Smad1 Signaling by Anti-Müllerian Hormone and Its Type II ReceptorJournal of Biological Chemistry, 2000
- Mutant Isoforms of the Anti-Müllerian Hormone Type II Receptor Are Not Expressed at the Cell MembranePublished by Elsevier BV ,1996